Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/ Ledipasvir in Iranian Patients (HepCC-2)

Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/ Ledipasvir in Iranian Patients (HepCC-2)

Hepatitis C virus (HCV) infection with around 0.5% and 2.2% prevalence in Iran and world is one of the public health problems resulting in chronic liver disease, cirrhosis and hepatocellular carcinoma. All cases of chronic HCV infections are candidates of treatment to prevent advanced liver diseases. The previous Pegylated-interferon and Ribavirin therapy was not efficient in all cases and results in numerous number of side-effects. Introduction of direct acting antiviral agents (DAAs) such as Sofosbuvir and Ledipasvir make the eradication of HCV possible however these regimens are not affordable and available in developing countries. The generic DAAs are manufactured in many of these countries such as Iran to provide the treatment with reasonable price.

To read the entire clinical trial description, click here